Prudential Financial’s First Tracks Biotherapeutics TRAX Stock Holding History

Prudential Financial’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Buy	+60,940	New	+$1.14M	﹤0.01%	1591

Other funds holding TRAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Prudential Financial's TRAX Position: Q2 2026 in Review

Prudential Financial opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 60,940 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #1591 among its holdings.

66 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Prudential Financial held 60,940 shares of First Tracks Biotherapeutics worth $1.23M as of Q2 2026.
First Tracks Biotherapeutics was a new Prudential Financial position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1591 holding.
66 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.